Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity: 2010-2020

Historic Liabilities and Shareholders Equity for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2020 value amounting to $1.7 billion.

  • Neurocrine Biosciences' Liabilities and Shareholders Equity rose 34.25% to $2.0 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $7.6 billion, marking a year-over-year increase of 32.86%. This contributed to the annual value of $1.7 billion for FY2020, which is 32.83% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $1.7 billion for FY2020, which was up 32.83% from $1.3 billion recorded in FY2019.
  • In the past 5 years, Neurocrine Biosciences' Liabilities and Shareholders Equity registered a high of $1.7 billion during FY2020, and its lowest value of $365.1 million during FY2016.
  • For the 3-year period, Neurocrine Biosciences' Liabilities and Shareholders Equity averaged around $1.3 billion, with its median value being $1.3 billion (2019).
  • In the last 5 years, Neurocrine Biosciences' Liabilities and Shareholders Equity fell by 23.10% in 2016 and then soared by 123.94% in 2017.
  • Yearly analysis of 5 years shows Neurocrine Biosciences' Liabilities and Shareholders Equity stood at $365.1 million in 2016, then spiked by 123.94% to $817.6 million in 2017, then rose by 21.47% to $993.2 million in 2018, then soared by 31.50% to $1.3 billion in 2019, then skyrocketed by 32.83% to $1.7 billion in 2020.